Loading
companiesCompany
ANZUP Cancer Trials Group
aka Australian and New Zealand Urogenital and Prostate Cancer Trials Group, ANZUP
The Australian genitourinary trials group behind TheraP and proPSMA, the trials that put PSMA imaging and lutetium-PSMA therapy on the map.
Overview
Formed in 2008 to unite Australia and New Zealand's prostate, kidney, bladder, testicular and penile cancer researchers. ANZUP 1603 TheraP was the first randomised trial of lutetium-177 PSMA-617, showing higher PSA response than cabazitaxel and paving the way for VISION and the Pluvicto approval, and proPSMA (ANZUP 1702) showed PSMA PET-CT outperforms conventional imaging for staging high-risk prostate cancer. ENZAMET and ENZARAD tested enzalutamide with docetaxel and with radiotherapy. Trials are run through the NHMRC Clinical Trials Centre at the University of Sydney, and consumer advisory panels are built into every study.
Headquarters
Sydney, AU
Scorecard
All companies#192of 1243 companies, score 29
- approved products +6
- targets +2
- modalities +2
- regions +5
- 24-month regulatory events +4
- registry trials +10
1 approved, 0 in phase 3, 0 earlier, 1 targets, 25 registry studies. Formula on the scorecards page.
Website
Founded
2008
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Australian and New Zealand Urogenital and Prostate Cancer Trials Group, including child institutions. 3 works · 3 citations · 100% open access · 33% clinical trials · 0% reviews.
Oncology works per year
12022
02023
02024
12025
12026
Most works
- Margaret Mary McJannett1 works
- Hannah Williams1 works
- Andrew David Redfern1 works
- Natasha Anne Roberts1 works
- Cynthia Hawks1 works
- Janett Stoehr1 works
- Max Nobis1 works
- Ellie T. Y. Mok1 works
- Amy E. McCart Reed1 works
- C. Elizabeth Caldon1 works
Most cited
| Work | Journal | Year | Citations |
|---|---|---|---|
| The impact of coronavirus disease 2019 on genitourinary and prostate cancer care and clinical trials: A qualitative exploration of the Australian and New Zealand experience 10.1111/ajco.13847 · open access | Asia-Pacific Journal of Clinical Oncology | 2022 | 2 |
| Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling 10.1038/s41467-026-70683-x · open access | Nature Communications | 2026 | 1 |
| G‐ DISCO : Gemcitabine‐Docetaxel Intravesical Synchronous CO ‐administration – a phase 1 study protocol 10.1111/bju.70042 · open access | British Journal of Urology | 2025 | 0 |
Declan G. Murphy
Director of Genitourinary Oncology, Peter MacCallum Cancer Centre
Urological surgeryPSMA PETRobotic prostatectomy
Urologist who co-led proPSMA, the trial that showed PSMA PET should replace CT and bone scan for staging prostate cancer.
Ian Davis
Chair
Genitourinary oncologyProstate cancerClinical trials
Melbourne medical oncologist who chairs ANZUP, the Australia and New Zealand urogenital and prostate cancer trials group.
Samantha Oakes
CEO
Cancer research managementBreast and prostate cancer biologyClinical trials operations
Cancer biologist turned research executive who serves as CEO of the ANZUP Cancer Trials Group.
Michael Hofman
Professor of Nuclear Medicine; Director, Prostate Cancer Theranostics and Imaging Centre of Excellence
TheranosticsPSMA PETLutetium-PSMA therapy
Led proPSMA and TheraP, the trials that proved PSMA PET beats conventional imaging and that lutetium-PSMA beats chemotherapy.
Shahneen Sandhu
Medical oncologist; Lead, Genitourinary Oncology Theranostics, Peter Mac
Prostate cancerTheranosticsMelanoma
Runs the medical oncology side of Peter Mac's theranostics programme, combining lutetium-PSMA with hormonal and immune therapies.
Notes
top- TheraP (Lu-PSMA vs cabazitaxel)
- proPSMA (PSMA PET staging)
- ENZAMET / ENZARAD
- Bladder and kidney cancer trials
- Consumer involvement
Similar pages
not linked directly; found by shared links- CompanyBreast Cancer Trials
Shares Cancer Council Australia, Peter MacCallum Cancer Centre and the tag cooperative-group.
- CompanyMRC Clinical Trials Unit at UCL
Shares Prostate cancer and the tag cooperative-group.
- CompanyNRG Oncology
Shares Prostate cancer and the tag cooperative-group.
- PersonLinda Mileshkin
Shares Peter MacCallum Cancer Centre and the tag cooperative-group.
- PersonShankar Siva
Shares TROG Cancer Research, Peter MacCallum Cancer Centre, Renal cell carcinoma, Prostate cancer.
- PairingPSMA PET → PSMA radioligand therapy
Shares Theranostics, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
- InstitutionChulabhorn Hospital / Chulabhorn Royal Academy
Shares Theranostics, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
- TreatmentLocametz (kit for Ga-68 gozetotide)
Shares Theranostics, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
cancers
3fronts
1technologies
3drugs
1ApprovedRadioligand therapy (beta)
Lutetium-177 vipivotide tetraxetan · Pluvicto